Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population
about
Selective use of sorafenib in the treatment of thyroid cancerSignaling Pathways in Thyroid Cancer and Their Therapeutic ImplicationsThe Evolving Treatment Landscape for Metastatic Differentiated Thyroid CancerMultikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinibSorafenib in metastatic thyroid cancer: a systematic reviewTreatment strategies for radioactive iodine-refractory differentiated thyroid cancerOptimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directionsProgress in molecular-based management of differentiated thyroid cancerCurrent status and future perspectives in differentiated thyroid cancerAutophagy in thyroid cancer: present knowledge and future perspectives2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid CancerA multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer.Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib.Alternative medical treatment for radioiodine-refractory thyroid cancers.Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer.Molecular pathogenesis and mechanisms of thyroid cancerA Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses.Multikinase inhibitors use in differentiated thyroid carcinoma.Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients.Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trialNew therapies for dedifferentiated papillary thyroid cancerDiagnosis, treatment, and follow-up of medullary thyroid carcinoma: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism.Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational statusThe Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune CellsTreatment compliance and severe adverse events limit the use of tyrosine kinase inhibitors in refractory thyroid cancer.Thyroid cancer: molecular aspects and new therapeutic strategies.A rare adverse reaction of sorafenibThe discovery and development of sorafenib for the treatment of thyroid cancer.Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic ReviewNew treatment in advanced thyroid cancer.New insight into the treatment of advanced differentiated thyroid cancer.First-Line Use of Vemurafenib to Enable Thyroidectomy and Radioactive Iodine Ablation for BRAF-Positive Metastatic Papillary Thyroid Carcinoma: A Case ReportAdvanced medullary thyroid cancer: pathophysiology and managementEvolving approaches to patients with advanced differentiated thyroid cancerCurrent understanding and management of medullary thyroid cancer.Sorafenib in metastatic radioactive iodine-refractory differentiated thyroid cancer: A pilot study.Multikinase inhibitors: a new option for the treatment of thyroid cancer.Pharmacotherapy options for advanced thyroid cancer: a systematic review.Differentiated thyroid cancers: a comprehensive review of novel targeted therapies.
P2860
Q26752891-15A4E1A9-22E8-463E-8489-FEA04CE930A0Q26764899-0E2EC906-A4B1-40DC-BA10-D8891501F5E9Q26795503-E3BDD440-7F7A-42EC-8854-6848F674C341Q26821959-8146833D-F1C2-48D6-9935-BAE4FD4E2A8EQ26828884-73FD1DF3-08E2-410C-86D2-A381CB836D87Q26862841-186D0A05-4302-4A5A-96D9-5C0AA25DFC07Q26863326-B8759F13-2A40-43C6-B3D8-F7E8FBD0E2D1Q26999887-B7B3641B-0EF7-4606-9475-DFEAB12F34E9Q27024484-25E08F48-8596-49F9-B625-C58092FF1B49Q28086785-52AB83BF-BCD7-4EC7-A678-74D6B9F44AFCQ30367068-CB7387A0-250C-4BF4-AE90-B8D1194A3DC2Q33569049-C90A13BB-6D7A-4A09-81B2-B6D9811E3265Q33577870-E98C8D2C-BB00-4D44-BD17-65BDC075460FQ33682381-0494F948-3F8A-4AF0-A4DF-5DA061B12DC3Q33704599-6974ED22-A58E-408A-85CD-94A9C9014CEAQ33927272-BA5DD1A3-4515-4D2B-BDEF-F079D3EEB109Q34329018-62F0F87B-D305-4FBA-9188-374EDA563086Q34538390-1BE8028D-1DBC-4C9D-8A3C-7CBCCE092CBEQ34660901-8FB3F434-F239-4D55-9A34-68DF3C2A0955Q35057314-6570DDFE-A2D7-4B5C-A5C7-3A288F6A19CAQ35195766-CADA5DE0-DF59-40F8-91D1-10CB2E37B4E8Q35381593-97860C2A-5EFD-458B-AF06-693EA77650AFQ35396089-2AA408E2-F8D4-4EF8-B7BB-96DBFEB0A4BBQ35603183-8EC1014E-FA3B-49B1-B608-3112B264A89DQ35988731-9463191B-A704-4BE6-9675-C2DC319953F5Q36037051-99CF9BA6-499F-45F2-9DEE-BC7AFD71E89EQ36111541-58500A06-ADE6-4B39-A322-427119F18A7CQ36180063-363EF1CA-A5C4-4669-BB85-17521ACEFC09Q36263304-D8C688C4-4A80-4FD8-B1D6-223878B96D14Q36270115-9BE73FBD-CA3E-4621-A01F-B3220578BF25Q36361115-5993D451-A93E-4F86-8EE6-7284E02CDCECQ36528466-CEE680AA-DF3B-4F25-9801-0BF93F6D6D86Q36565803-29B356BB-AC1E-47DC-BFC1-EAC76F79B511Q36857218-CF079CD0-9C2E-4902-B3D9-DD2C1F599575Q36864736-0EAB7C52-B52F-4AD5-8564-3676CC08A741Q37247181-3286CDEE-762F-44EB-AB07-155496C158D4Q37562646-2D6B9482-414C-4229-85C4-BF072FB7C2BFQ37921602-5F85A46E-630B-496A-BAA5-4F8217001BC4Q37970758-F6CB5B89-47AB-4EBB-8566-2C61DEC031B1Q37988566-75E7B6E8-2AB7-4989-98B6-8D54886A2DAB
P2860
Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population
description
article
@en
im August 2011 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в серпні 2011
@uk
name
Analysis of the efficacy and t ...... study in a UK based population
@en
Analysis of the efficacy and t ...... study in a UK based population
@nl
type
label
Analysis of the efficacy and t ...... study in a UK based population
@en
Analysis of the efficacy and t ...... study in a UK based population
@nl
prefLabel
Analysis of the efficacy and t ...... study in a UK based population
@en
Analysis of the efficacy and t ...... study in a UK based population
@nl
P2093
P356
P1476
Analysis of the efficacy and t ...... study in a UK based population
@en
P2093
Amaya Viros
Angela Riddell
Christopher M Nutting
Jen Hickey
Katie L Newbold
Kevin J Harrington
Merina Ahmed
Yolanda Barbachano
P304
P356
10.1530/EJE-11-0129
P577
2011-08-01T00:00:00Z